This article is more than 5 years old. Information may no longer be current.

Provectus announces Q2 financial results, updates on psoriasis, AD, melanoma therapies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Provectus Biopharmaceuticals announced financial results of its second quarter of 2015 and provided updates on the development of new therapies for dermatology and oncology.

The company announced cash and cash equivalents of $23,117,114 on June 30, 2015, compared with $17,391,601 at Dec. 31, 2014, according to a press release. Stockholders’ equity was $30,246,789 on June 30, 2015, compared with $25,189,876 on Dec. 31, 2014.

Provectus provided updates on its investigational therapies, including PV-10, which has received orphan drug status from the FDA for its melanoma and hepatocellular indications.

Phase 2 trials of PV-10 for treating metastatic melanoma have completed, and a phase 3 trial has begun. PV-10 is designed for injection into solid tumors, which reduces potential for systemic side effects, according to the release

PH-10, its topical treatment for psoriasis and atopic dermatitis, is undergoing clinical testing, the company announced. Phase 2 trials PH-10 have been completed, according to the release.

Reference: www.pvct.com